Crop Life Science Releases Audited Financial Results for Half Year and Year Ended March 31, 2026
Crop Life Science Limited announced the approval of its Audited Standalone and Consolidated Financial Results for the half year and financial year ended March 31, 2026. The results reflect the performance of both the company and its subsidiary, Hetban Spechem Limited, for the reporting periods.The Board of Directors approved the financial results during the meeting held on May 26, 2026.
Consolidated Financial Performance Highlights
The company reported significant figures across its consolidated financial results. Total income for the year ended March 31, 2026, stood at 20,894.42 INR Lacs, compared to 20,160.73 INR Lacs in the previous year.Total comprehensive income for the year was 665.15 INR Lacs for the year ended March 31, 2026, showing a substantial increase from 543.77 INR Lacs in the prior year. Profit for the half year ended March 31, 2026, was 357.54 INR Lacs.
The following table summarizes the key financial metrics for the consolidated entity:
| Metric (INR in Lacs) | Half Year Ended 31-Mar-26 | Half Year Ended 30-Sep-25 | Half Year Ended 31-Mar-25 | Year Ended 31-Mar-26 | Year Ended 31-Mar-25 |
|---|---|---|---|---|---|
| Total Income | 8,792.36 | 12,102.06 | 9,513.13 | 20,894.42 | 20,160.73 |
| Total Expenses | 8,241.37 | 11,736.11 | 9,112.70 | 19,977.48 | 19,381.15 |
| Profit Before Tax | 550.99 | 365.95 | 400.43 | 916.94 | 779.58 |
| Total Tax Expense | 158.42 | 115.31 | 117.58 | 273.73 | 219.47 |
| Total Comprehensive Income | 384.88 | 280.27 | 266.51 | 665.15 | 543.77 |
| Basic EPS (INR) | 1.48 | 2.31 | 1.55 | 3.79 | 3.27 |
Assets and Liabilities Snapshot
The balance sheet summary for the consolidated group shows changes in asset and liability structures:| Particulars (INR in Lacs) | As at March 31, 2026 | As at March 31, 2025 |
|---|---|---|
| Total Non-current Assets | 3,129.44 | 3,952.63 |
| Total Current Assets | 17,140.00 | 18,170.58 |
| Total Assets | 20,269.44 | 22,123.21 |
| Total Equity | 7,086.12 | 6,420.96 |
| Total Liabilities | 13,183.32 | 15,702.25 |
Cash Flow Generation
Cash flow activities indicate the group's operational and financing movements. The Consolidated Statement of Cash Flows details the following:| Activity | Year Ended March 31, 2026 | Year Ended March 31, 2025 |
|---|---|---|
| Cash flow generated from operations (A) | (763.13) | (149.81) |
| Cash flow from investing activities (B) | 157.67 | (410.53) |
| Cash flow from financing activities (C) | N/A | N/A |
| Net Increase/Decrease in Cash and Cash Equivalents (A + B + C) | N/A | N/A |
| Cash and cash equivalents at the end of the year | (5,037.55) | (3,498.74) |
(Note: The cash flow table provides net figures for the years ended March 31, 2026, and March 31, 2025.)
Standalone Financial Updates
Standalone results for Crop Life Science Limited also presented key movements. The total comprehensive income for the standalone entity reached 714.35 INR Lacs for the year ended March 31, 2026, compared to 645.69 INR Lacs in the previous year.The Standalone Balance Sheet highlights the following key changes:
| Particulars (INR in Lacs) | As at March 31, 2026 | As at March 31, 2025 |
|---|---|---|
| Total Assets | 20,531.7 | 17,770.69 |
| Total Equity | 8,534.52 | 7,820.18 |
| Total Liabilities | 12,000.00 | 9,950.51 |
The results for the half year and year ended March 31, 2026, are available on the company's website.
CLSL Stock Price Movement
Today, Crop Life Science Limited shares edged higher to close at ₹44.2, gaining 6.12% in after-hours trading. The stock saw a trading volume of 12,000 shares as investors finished the day on an optimistic note.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: